- Home
- TJGC vs MREO Comparison
TJGC vs MREO Comparison
Compare TJGC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | MREO |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 50.3M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TJGC | MREO |
|---|---|---|
| Price | $10.51 | $0.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 1.7M | ★ 5.2M |
| Earning Date | 08-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $0.20 |
| 52 Week High | $10.80 | $2.37 |
Technical Indicators
Market Signals| Indicator | TJGC | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 83.78 | 36.56 |
| Support Level | $4.11 | $0.22 |
| Resistance Level | N/A | $0.35 |
| Average True Range (ATR) | 0.98 | 0.02 |
| MACD | 0.44 | -0.00 |
| Stochastic Oscillator | 94.73 | 12.61 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).